Micaël De Meyer, et al. Journal for Immunotherapy of Cancer, [...]
TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.
Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – [...]
Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.
Houda Boukhebza, et al. Journal of Hepatology, 2013, (58), Supplement [...]
130 – A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.
Perrine Martin, et al. Journal of Hepatology, 2013, (58), Supplement [...]
Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)
link J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. [...]
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans
Mi Kyung Kim, et al. Science Translational Medicine. 2013 May [...]
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo, et al. Nature Medicine, 2013 (3):329-36. doi: 10.1038/nm.3089. [...]
Jean-Marc Limacher, et al. Expert Review of Vaccines, 2013; 12(3): [...]